SWOG clinical trial number
S0331
A Phase II Trial of STI-571/Imatinib (Gleevec®) (NSC-716051) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)
62% Accrual
Accrual
62%
Closed
Phase
62% Accrual
Accrual
62%
Published
Research committees
Melanoma
Treatment
STI-571/Imatinib
Eligibility Criteria Expand/Collapse
Publication Information Expand/Collapse
Other Clinical Trials
S2000
SWOG Clinical Trial Number
Research Committee(s)
Melanoma
Activated
09/23/2020
100% Accrual
Accrual
100%
Open
Phase
CTSU/EA6174
SWOG Clinical Trial Number
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
CTSU/EA6141
SWOG Clinical Trial Number
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase